Perspective, the one most responsive to change

Nuclear Medicine and Biology

Volumn 41, Issue 4, 2014, Pages 297-298

  Eckelman, William C ^a   Lau, Chuen Yen ^b   Neumann, Ronald D ^c  

^a Molecular Tracer LLC   (United States)

^b National Institute of Allergy and Infectious Disease   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOPHARMACEUTICAL AGENT;

DNA REPLICATION; DRUG BINDING; DRUG TARGETING; EDITORIAL; GENE FREQUENCY; GENE MAPPING; GENETIC VARIABILITY; HIGH THROUGHPUT SEQUENCING; ISOTOPE LABELING; MOLECULAR IMAGING; MOLECULAR PROBE; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIATION ABSORPTION; SINGLE NUCLEOTIDE POLYMORPHISM;

DRUG DISCOVERY; MOLECULAR IMAGING; RADIOPHARMACEUTICALS;

EID: 84895440081     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.10.002     Document Type: Editorial

References (17)

1. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2. Eckelman WC, Jones AG, Duatti A, Reba RC. Progress using Tc-99m radiopharmaceuticals for measuring high capacity sites and low density sites. Drug Discov Today. 2013 Jun 24. doi:pii: S1359-6446(13)00171-2. 10.1016/j.drudis.2013.06.008. [Epub ahead of print].
3. Eckelman W.C. Targeted molecular imaging: target significance and probe validation. JACC Cardiovasc Imaging. 2012, 5:616-618.
4. Eckelman W. Changes: choosing a target?. Nucl Med Biol. 2011, 38:765-769.
5. Roden D.M., Tyndale R.F. Genomic medicine, precision medicine, personalized medicine: what's in a name?. Clin Pharmacol Ther. 2013, 94:169-172.
6. Haber E. Antibodies as models for rational drug design. Biochemical Pharmacology 1983, 13:1967-1977.
7. Gashaw I., Ellinghaus P., Sommer A., et al. What makes a good drug target?. Drug Discovery Today 2011, 16:1037-1043.
8. Manolio T.A., Collins F.S., Cox N.J., et al. Finding the missing heritability of complex diseases. Nature 2009, 461:747-753.
9. Ishak M.B., Giri V.N. A systematic review of replication studies of prostate cancer susceptibility genetic variants in high-risk men originally identified from genome-wide association studies. Cancer Epidemiol Biomarkers Prev. 2011, 20:1599-1610.
10. Tsuchiya N., Matsui S., Narita S., et al. Distinct cancer-specific survival in metastatic prostate cancer patients classified by a panel of single nucleotide polymorphisms of cancer-associated genes. Genes Cancer. 2013, 4:54-60.
11. Roychowdhury S., Chinnaiyan A.M. Advancing precision medicine for prostate cancer through genomics. J Clin Oncol. 2013, 31:1866-1873.
12. Eckelman W.C., Reba R.C., Kelloff G.J. Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine. Drug Discov Today. 2008, 13:748-759.
13. Gerlinger M., Rowan A.J., Horswell S. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012, 366:883-892.
14. Kawasaki Y., Freire E. Finding a better path to drug selectivity. Drug Discov Today. 2011, 16:985-990.
15. Carson R.E. Precision and accuracy considerations of physiological quantitation in PET. J Cereb Blood Flow Metab. 1991, 11:A45-A50.
16. Carson R.E. Mathematical modeling and compartmental analysis. Nuclear medicine: diagnosis and therapy 1996, 167-194. Thieme Press, New York. J. Harbert, R. Neumann, W.C. Eckelman (Eds.).
17. http://www.who.int/mediacentre/factsheets/fs310/en/index.html. Confirmed Sept 2013.